clinical trial · NCT04150887
Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia
OncoVerity, Inc.·phase1·active not recruiting·n = 61
Leukemia, Myeloid, AcuteCusatuzumabAzacitidineVenetoclax
brief summary
The purpose of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia (AML).
started
Dec 23, 2019
primary completion
May 15, 2026
completion
May 15, 2026
last updated
Apr 17, 2025
official title
An Open-label, Multicenter, Phase 1b Study of OV-1001 (Cusatuzumab; Anti-CD70 Monoclonal Antibody) in Combination With Background Therapy for the Treatment of Subjects With Acute Myeloid Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol